Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Targeted Diagnosis and Treatment of Coronary Artery Disease
share announcement

Targeted Diagnosis and Treatment of Coronary Artery Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1946

Special Issue Editor

Dr. Antonio Nenna

E-Mail Website
Guest Editor
Unit of Cardiovascular Surgery, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy
Interests: cardiac surgery; myocardial revascularization; angiogenesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Coronary artery disease remains a leading cause of morbidity and mortality worldwide. Efforts in preclinical and clinical research aim to improve life expectancy and quality of life while reducing healthcare-associated costs. Rigorous out-patient selection, the availability of safe and effective percutaneous devices and surgical techniques, and a careful research approach are crucial to ensuring these developments meet patients’ clinical needs. This Special Issue aims to provide an overview of the latest discoveries and new findings, analyses of previously published data, and new opinions and perspectives on targeted diagnosis and treatment in coronary artery disease. Original research articles and reviews are welcome. Research areas of interest include (but are not limited to) the following: myocardial circulation and pathophysiologic changes during ischemia and after revascularization; percutaneous coronary intervention, with an emphasis on emerging techniques and technologies; coronary artery bypass graft, with an emphasis on functional-based revascularization or total arterial revascularization; intravascular ultrasound (IVUS); fractional flow reserve (FFR); instantaneous wave-free ratio (iFR); and angiogenesis following percutaneous or surgical revascularization.

Dr. Antonio Nenna
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • myocardial revascularization
  • percutaneous coronary intervention
  • cardiac surgery
  • coronary artery bypass graft
  • intravascular ultrasound
  • fractional flow reserve
  • instantaneous wave-free ratio
  • angiogenesis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 401 KiB  
Article
Anti-Anginal Efficacy of Zibotentan in the Coronary Slow-Flow Phenomenon
by Sivabaskari Pasupathy, Rosanna Tavella, Christopher Zeitz, Suzanne Edwards, Matthew Worthley, Margaret Arstall and John F. Beltrame
J. Clin. Med. 2024, 13(5), 1337; https://doi.org/10.3390/jcm13051337 - 27 Feb 2024
Viewed by 545
Abstract
Background: Patients with coronary microvascular disorders often experience recurrent angina for which there are limited evidence-based therapies. These patients have been found to exhibit increased plasma levels of endothelin; thus, selective endothelin–A (Et-A) receptor blockers such as zibotentan may be an effective anti-anginal [...] Read more.
Background: Patients with coronary microvascular disorders often experience recurrent angina for which there are limited evidence-based therapies. These patients have been found to exhibit increased plasma levels of endothelin; thus, selective endothelin–A (Et-A) receptor blockers such as zibotentan may be an effective anti-anginal therapy in these patients. The study evaluated the impact of a 10 mg daily dose of zibotentan on spontaneous angina episodes in patients with the coronary slow-flow phenomenon who had refractory angina (i.e., experiencing angina at least three times/week despite current anti-anginal therapy). Methods: Using a randomized, double-blind, placebo-controlled, crossover trial design with 4-week treatment periods, 18 patients (63.2 ± 9.9 years, 33% females) were recruited. The primary endpoint was angina frequency as measured by an angina diary, with secondary endpoints including nitrate consumption, angina duration/severity and the Seattle Angina Questionnaire (SAQ) domains. Results: During the 4 weeks of therapy, angina frequency significantly improved with zibotentan therapy (placebo 41.4 (58.5) vs. zibotentan 29.2 (31.6), p < 0.05), and sublingual nitrate consumption significantly reduced (placebo 11.8 (15.2) vs. zibotentan 8.8 (12.9), p < 0.05. Conclusions: Zibotentan improved the frequency of spontaneous angina episodes and reduced sublingual nitrate consumption in patients unresponsive to standard anti-anginal therapy. Full article
(This article belongs to the Special Issue Targeted Diagnosis and Treatment of Coronary Artery Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 521 KiB  
Review
Cholesterol-Lowering Strategies for Cardiovascular Disease Prevention: The Importance of Intensive Treatment and the Simplification of Medical Therapy
by Vincenzo Sucato, Antonella Ortello, Francesco Comparato, Giuseppina Novo and Alfredo Ruggero Galassi
J. Clin. Med. 2024, 13(7), 1882; https://doi.org/10.3390/jcm13071882 - 25 Mar 2024
Viewed by 839
Abstract
Cardiovascular diseases (CVDs) are a leading global cause of mortality and are primarily driven by atherosclerotic coronary artery disease. Their pathogenesis involves multi-factorial mechanisms, among which low-density lipoprotein (LDL) plays a causative role. Recent ESC/EAS guidelines advocate for a shift toward new risk [...] Read more.
Cardiovascular diseases (CVDs) are a leading global cause of mortality and are primarily driven by atherosclerotic coronary artery disease. Their pathogenesis involves multi-factorial mechanisms, among which low-density lipoprotein (LDL) plays a causative role. Recent ESC/EAS guidelines advocate for a shift toward new risk estimation algorithms that better emphasize non-fatal cardiovascular events, lifetime risk prediction, and tailored pharmacological approaches, including statin + ezetimibe and triple therapy, in specific cases. Intensive lipid-lowering therapy has been shown to be pivotal, especially in post-acute coronary events. Intracoronary imaging has revealed insights into the composition of plaque and demonstrated the significant regression that can be achieved through the use of statins such as rosuvastatin and atorvastatin. The positive effects of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, particularly alirocumab and evolocumab, on plaque regression, have been demonstrated. Inclisiran, which targets PCSK9 gene expression, significantly reduces LDL cholesterol. The associated challenges include hesitancy to prescribe intensive regimens and limited treatment adherence, highlighting the need for pharmacological combinations to improve therapeutic outcomes. Full article
(This article belongs to the Special Issue Targeted Diagnosis and Treatment of Coronary Artery Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop